Silence Therapeutics is developing a pipeline of siRNA (short interfering RNA) therapeutics using its proprietary mRNA GOLD™ platform. Silence’s pipeline includes wholly owned and partnered programs aimed to address genetic diseases with high unmet need. SLN124 is Silence’s wholly owned product candidate in clinical development for beta thalassemia and polycythemia vera. SLN124 works by silencing the TMPRSS6 gene and has demonstrated pre-clinical potential in a range of hematological diseases.